Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Nefecon, the gut-targeted formulation of budesonide, designed to modulate gut-associated lymphoid tissue and suppress the synthesis of galactose-deficient IgA1, has shown significant efficacy in reducing proteinuria and preserving renal function in patients with IgA nephropathy (IgAN). However, real-world evidence regarding its efficacy and safety as an initial therapeutic option in the broader IgAN population remains limited.
This single-center retrospective study enrolled patients who were newly diagnosed with primary IgAN. All patients presented with persistent proteinuria (UPCR ≥ 0.5 mg/mg or 24-hour urinary protein [24h UP] ≥ 0.5 g/day) despite optimized supportive therapy and had an eGFR ≥ 10 mL/min/1.73 m². The primary endpoints were changes in 24h UP, UPCR, and urinary RBC count. Secondary outcomes included changes in eGFR and the assessment of adverse events.
A Total of 21 eligible patients with IgAN received Nefecon treatment. After 12 weeks of therapy, significant improvements were observed across multiple clinical parameters: The 24h UP decreased from 1.41 mg/mg (IQR 0.77–2.26) to 0.62 mg/mg (IQR 0.43–1.05) (P < 0.01), with a median reduction of –50.40% (IQR –77.84 to –16.90). The UPCR declined from 1.32mg/mg (IQR 0.69–1.99) to 0.35 mg/mg (IQR 0.17–0.74) (P < 0.01), corresponding to a median reduction of –73.26% (IQR –87.98 to –54.00). The urinary RBC count dropped from 90.80 cells/μL (IQR 42.70–195.50) to 36.60 cells/μL (IQR 15.33–108.80) (P < 0.01), reflecting a median reduction of –53.78% (IQR –81.45 to –6.95). In addition, eGFR increased from 55.27 ± 31.73 mL/min/1.73 m² to 61.50 ± 34.38 mL/min/1.73 m² (P < 0.01), with a median increase of 13.38% (IQR –3.02 to 31.17). No serious adverse events were reported during the treatment period.
Nefecon, as an initial therapeutic option for patients newly diagnosed with primary IgAN, was well tolerated and demonstrated a favorable efficacy profile, significantly reducing proteinuria and hematuria while improving renal function as reflected by eGFR.
